October 22, 2014
A Delaware federal judge ruled Wednesday that Pfizer Inc.'s patent for cancer drug Sutent was nonobvious and could stand, despite a challenge from Mylan Pharmaceuticals Inc. in Pfizer's suit seeking to stop its rival from introducing a generic version.